Heart Failure with Preserved Ejection Fraction (HFpEF) Clinical Trials

Find Heart Failure with Preserved Ejection Fraction (HFpEF) Clinical Trials Near You

Randomized Trial of ELEVATEd Cardiac Pacing Rate for Personalized Treatment of Heart Failure With Preserved Ejection Fraction (ELEVATE-HFpEF)

Status: Recruiting
Location: See all (34) locations...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

ELEVATE-HFpEF is a prospective, randomized, controlled, double-blinded, multi-center, global, interventional pivotal study evaluating the safety and efficacy of dual chamber personalized pacing compared to minimal or no pacing for the treatment of patients with heart failure with preserved ejection fraction (HFpEF).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 40
Healthy Volunteers: f
View:

• Age ≥ 40 years

• Documented EF ≥50% within the preceding 12 months

• HFpEF defined as:

‣ Documented worsening HF episode (either HF hospitalization or documented urgent clinic visit for HF with intravenous diuretics) within 12-months prior to baseline visit OR

⁃ Dyspnea on exertion and New York Heart Association (NYHA) ≥ class II symptoms AND AT LEAST ONE OF THE FOLLOWING CRITERIA:

• Interstitial / pulmonary edema on prior chest imaging in the last year AND current loop diuretic use for heart failure

∙ Elevated NT-proBNP in the last year defined as \>400 pg/m for patients with no AF or paroxysmal AF, or \>900 pg/ml for patients with ≥persistent AF

∙ Mean pulmonary capillary wedge pressure (PCWP) ≥15 mm Hg or LVEDP ≥16 mm Hg at rest on cardiac catheterization OR pulmonary artery diastolic and wedge pressure (PADP) ≥15 mm Hg at rest on implantable monitor (e.g., CardioMEMs)

∙ Echo criteria defined by ≥2 of:

‣ LV wall thickness ≥ 12 mm

⁃ LV mass index (BSA indexed LVH): sex at birth male \>115 g/m2, sex at birth female \>95 g/m2

⁃ Relative wall thickness ≥0.42

⁃ E/e' ≥15 in sinus rhythm (or \> 11 in the setting of atrial fibrillation) OR septal \<7 cm/s or lateral e' \<10cm/s

⁃ Tricuspid regurgitation (TR) velocity \>2.8 m/s

⁃ Left atrial (LA) enlargement, defined by LA volume index \>34 ml/m2

• Patient is on stable guideline indicated HF medical therapy (Class I recommendations) for at least 30 days

• Patient's average heart rate on baseline ambulatory electrocardiographic monitor is at least 5 bpm lower than their calculated personalized cardiac pacing rate (e.g. if a patient's personalized cardiac pacing rate is 70 bpm and their average heart rate on the ambulatory electrocardiographic monitor is less than or equal to 65 bpm the patient is eligible)

• Patient is willing and able to adhere to the protocol (e.g., patient is able to ambulate independently at baseline).

Locations
United States
Arizona
Banner - University Medical Center Phoenix
RECRUITING
Phoenix
California
Sutter Health Hospital
RECRUITING
San Francisco
Connecticut
Hartford Hospital
RECRUITING
Hartford
Florida
Cardiovascular Institute of Northwest Florida
RECRUITING
Panama City
Georgia
Emory University
RECRUITING
Atlanta
Kentucky
Norton Healthcare
RECRUITING
Louisville
Louisiana
Cardiovascular Institute of the South
RECRUITING
Houma
Missouri
Saint Lukes Mid America Heart Institute
RECRUITING
Kansas City
Ohio
Mount Carmel East
RECRUITING
Columbus
The Ohio State University Wexner Medical Center
RECRUITING
Columbus
Pennsylvania
Lancaster General Hospital
RECRUITING
Lancaster
Lankenau Institute for Medical Research
RECRUITING
Wynnewood
South Carolina
Medical University of South Carolina (MUSC)
RECRUITING
Charleston
Tennessee
Saint Thomas Research Institute
RECRUITING
Nashville
Texas
Dallas VA Medical Center
RECRUITING
Dallas
Virginia
Inova Fairfax Hospital
RECRUITING
Falls Church
Vermont
The University of Vermont Medical Center
RECRUITING
Burlington
West Virginia
Charleston Area Medical Center (CAMC) Memorial Hospital
RECRUITING
Charleston
Other Locations
Australia
The Prince Charles Hospital
RECRUITING
Chermside
The Alfred Hospital
RECRUITING
Melbourne
Austria
Ordensklinikum Linz GmbH / Elisabethinen
RECRUITING
Linz
Belgium
Universitair Ziekenhuis Antwerpen
RECRUITING
Edegem
Canada
Saint Pauls Hospital
RECRUITING
Vancouver
France
Centre Hospitalier Universitaire Besancon - Hôpital Jean Minjoz
RECRUITING
Besançon
Centre Hospitalier Universitaire de Clermont-Ferrand - Gabriel-Montpied
RECRUITING
Clermont-ferrand
CHU Toulouse - Hôpital Rangueil
RECRUITING
Toulouse
Hong Kong Special Administrative Region
Prince of Wales Hospital
RECRUITING
Hong Kong
Queen Elizabeth Hospital (Hong Kong)
RECRUITING
Hong Kong
Malaysia
Sarawak Heart Centre
RECRUITING
Kota Samarahan
Norway
Oslo Universitetssykehus-Rikshospitalet
RECRUITING
Oslo
Slovenia
University Medical Centre Ljubljana
RECRUITING
Ljubljana
Switzerland
Hôpitaux Universitaires de Genève
RECRUITING
Geneva
United Kingdom
The Leeds Teaching Hospitals NHS Trust - Leeds General Infirmary
RECRUITING
Leeds
Manchester University NHS Foundation Trust - Manchester Royal Infirmary
RECRUITING
Manchester
Contact Information
Primary
Dawn Dyer
dawn.dyer@medtronic.com
954-682-8334
Time Frame
Start Date: 2025-07-09
Estimated Completion Date: 2029-02
Participants
Target number of participants: 700
Treatments
Experimental: Personalized Pacing Therapy (Treatment Group)
The treatment group will receive a qualifying Medtronic dual chamber pacemaker limited to Astra XT or Azure XT and programmed to provide dual chamber pacing at a personalized cardiac pacing rate determined by patient height and baseline LVEF percentage.
No_intervention: Control Group
The control group will receive a qualifying Medtronic dual chamber pacemaker limited to Astra XT or Azure XT and programmed to provide ventricular pacing at a non-personalized rate. This is considered limited or backup pacing.
Sponsors
Leads: Medtronic Cardiac Rhythm and Heart Failure

This content was sourced from clinicaltrials.gov